Everolimus
Active ingredient: Everolimus
In short: Everolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunologic risk receiving a kidney transplant. Everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids.
What is Everolimus used for?
Everolimus is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunologic risk receiving a kidney transplant. Everolimus is to be administered in combination with basiliximab induction and concurrently with reduced doses of cyclosporine and with corticosteroids. Therapeutic drug monitoring (TDM) of everolimus and cyclosporine is recommended for all patients receiving these products.
Everolimus is indicated for the prophylaxis of allograft rejection in adult patients receiving a liver transplant. Everolimus is to be administered no earlier than 30 days posttransplant concurrently in combination with reduced doses of tacrolimus and with corticosteroids. TDM of everolimus and tacrolimus is recommended for all patients receiving these products.
The safety and efficacy of everolimus has not been established in the following populations:
•Kidney transplant patients at high immunologic risk.
•Recipients of transplanted organs other than kidney and liver .
•Pediatric patients (less than 18 years).
âš Boxed warning (FDA's strongest warning)
Malignancies and Serious Infections
•
Only physicians experienced in immunosuppressive therapy and management of transplant patients should prescribe everolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient .
•
Increased susceptibility to infection and the possible development of malignancies, such as lymphoma and skin cancer, may result from immunosuppression .
Kidney Graft Thrombosis
•
An increased risk of kidney arterial and venous thrombosis, resulting in graft loss, was reported, mostly within the first 30 days posttransplantation .
Nephrotoxicity
•
Increased nephrotoxicity can occur with use of standard doses of cyclosporine in combination with everolimus. Therefore, reduced doses of cyclosporine should be used in combination with everolimus in order to reduce renal dysfunction. It is important to monitor the cyclosporine and everolimus whole blood trough concentrations [
see Dosage and Administration (2.5,
2.6
), Warnings and Precautions (5.6), Clinical Pharmacology (12.7,
12.8
)].
Mortality in Heart Transplantation
•
Increased mortality, often associated with serious infections, within the first three months posttransplantation was observed in a clinical trial of de novo heart transplant patients receiving immunosuppressive regimens with or without induction therapy. Use in heart transplantation is not recommended .
Everolimus dosage
Everolimus tablets should be swallowed whole with a glass of water.
Do not crush everolimus tablets.
Administer everolimus tablets consistently approximately 12 hours apart with or without food to minimize variability in absorption and at the same time as cyclosporine or tacrolimus .
Patients receiving everolimus may require dose adjustments based on everolimus blood concentrations achieved, tolerability, individual response, change in concomitant medications and the clinical situation. Optimally, dose adjustments of everolimus should be based on trough concentrations obtained 4 or 5 days after a previous dosing change. Dose adjustment is required if the trough concentration is below 3 ng/mL. The total daily dose of everolimus should be doubled using the available tablet strengths (0.25 mg, 0.5 mg, 0.75 mg, or 1 mg). Dose adjustment is also required if the trough concentration is greater than 8 ng/mL on 2 consecutive measures; the dose of everolimus should be decreased by 0.25 mg twice daily .
The initial recommended dosage of everolimus tablets, in combination with reduced-dose cyclosporine, in adult patients with a kidney transplant is 0.75 mg orally twice daily (1.5 mg per day), administered as soon as possible after transplantation .
Oral prednisone shouldbe initiated once oral medication is tolerated. Steroid doses may be further tapered on an individualized basis depending on the clinical status of patientand function of graft.
Start everolimus at least 30 days posttransplant. The initial recommended dosage of everolimus tablets, in combination with reduced-dose tacrolimus, in adult patients with a liver transplant is 1 mg orally twice daily (2 mg per day) .
Steroid doses may be further tapered on an individualized basis depending on the clinical status of patient and function of graft.
Routine everolimus whole blood therapeutic drug concentration monitoring is recommended for all patients. The recommended everolimus therapeutic range is 3 to 8 ng/mL . Careful attention should be made to clinical signs and symptoms, tissue biopsies, and laboratory parameters. It is important to monitor everolimus blood concentrations, in patients with hepatic impairment, during concomitant administration of CYP3A inducers or inhibitors or cannabidiol, when switching cyclosporine formulations and/or when cyclosporine dosing is reduced according to recommended target concentrations .
There is an interaction of cyclosporine on everolimus, and consequently, everolimus concentrations may decrease if cyclosporine exposure is reduced. There is little to no pharmacokinetic interaction of tacrolimus on everolimus, and thus, everolimus concentrations do not decrease if the tacrolimus exposure is reduced . …
How to take Everolimus — instructions & advice from the label
Advise patients to read the FDA-approved patient labeling (Medication Guide).
Administration
Inform patients that everolimus should be taken orally twice a day approximately 12 hours apart consistently either with or without food.
Inform patients to avoid grapefruit and grapefruit juice, which increase blood drug concentrations of everolimus .
Advise patients that everolimus should be used concomitantly with reduced doses of cyclosporine and that any change in doses of these medications should be made under physician supervision. A change in the cyclosporine dose may also require a change in the dosage of everolimus.
Inform patients of the necessity of repeated laboratory tests according to physician recommendations while they are taking everolimus.
Lymphomas and Other Malignancies
Inform patients they are at risk of developing lymphomas and other malignancies, particularly of the skin, due to immunosuppression. Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and using a sunscreen with a high protection factor . …
Warnings & precautions
Do not take this medicine if: Hypersensitivity Reactions
Everolimus is contraindicated in patients with known hypersensitivity to everolimus, sirolimus, or to any of its excipients.
Only physicians experienced in management of systemic immunosuppressant therapy in transplantation should prescribe everolimus. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for the maintenance therapy should have complete information requisite for the follow-up of the patient. In limited data with the complete elimination of calcineurin inhibition (CNI), there was an increased risk of acute rejection.
Patients receiving immunosuppressants, including everolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent.
As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.
Patients receiving immunosuppressants, including everolimus, are at increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections . These infections may lead to serious, including fatal, outcomes. Because of the danger of over-immunosuppression, which can cause increased susceptibility to infection, combination immunosuppressant therapy should be used with caution.
Antimicrobial prophylaxis for Pneumocystis jiroveci (carinii) pneumonia and prophylaxis for cytomegalovirus (CMV) is recommended in transplant recipients. …
Everolimus side effects
The following adverse reactions are discussed in greater detail in other sections of the label.
•Hypersensitivity Reactions
•Lymphomas and Other Malignancies
•Serious Infections
•Kidney Graft Thrombosis
•Hepatic Artery Thrombosis
•Everolimus and Calcineurin Inhibitor-Induced Nephrotoxicity
•Heart Transplantation
•Angioedema
•Wound Healing and Fluid Accumulation
•Interstitial Lung Disease/Non-Infectious Pneumonitis
•Hyperlipidemia
•Proteinuria
•Polyoma Virus Infections
•Thrombotic Microangiopathy/Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TMA/TTP/HUS)
•New Onset Diabetes After Transplant
•Male Infertility
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials of another drug and may not reflect the rates observed in clinical practice.
Kidney Transplantation
Adverse reactions in everolimus was derived from an open-label, randomized trial of de novo kidney transplant patients of concentration-controlled everolimus at an initial everolimus starting dose of 1.5 mg per day [target trough concentrations 3 to 8 ng/mL with reduced exposure cyclosporine (N=274) compared to mycophenolic acid (N=273) with standard exposure cyclosporine]. All patients received basiliximab induction therapy and corticosteroids. …
Drug interactions
Everolimus is mainly metabolized by CYP3A in the liver and to some extent in the intestinal wall and is a substrate for the multidrug efflux pump, P-glycoprotein (P-gp). Therefore, absorption and subsequent elimination of orally absorbed everolimus may be influenced by medicinal products that affect CYP3A and/or P-gp.
Strong or Moderate Inhibitors of CYP3A
Inhibitors of CYP3A may increase concentrations of everolimus and result in more adverse events. Avoid concomitant treatment with strong inhibitors of CYP3A. When used with moderate inhibitors of CYP3A, everolimus blood concentrations should be monitored and a dose reduction made as necessary .
Strong or Moderate Inducers of CYP3A
Inducers of CYP3A may decrease concentrations of everolimus and make it less effective. Avoid concomitant treatment with strong inducers of CYP3A. When used with moderate inducers of CYP3A, everolimus blood concentrations should be monitored and a dose increase made as necessary .
Cyclosporine (P-gp/weak CYP3A Inhibitor)
The Cmax and area under the curve (AUC) of everolimus were significantly increased by cyclosporine . Dose adjustment of everolimus might be needed if the cyclosporine dose is altered . …
About this medicine
Everolimus Tablets are a macrolide immunosuppressant.
The chemical name of everolimus is (1R, 9S, 12S, 15R, 16E, 18R, 19R, 21R, 23S, 24E, 26E, 28E, 30S, 32S, 35R)-1, 18-dihydroxy-12 -{(1R)-2-[(1S,3R,4R)4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15, 17, 21, 23, 29, 35-hexamethyl-11, 36-dioxa-4-aza-tricyclo[30.3.1.04,9] hexatriaconta-16,24,26,28-tetraene-2, 3,10,14,20-pentaone.
The molecular formula is C53H83NO14 and the molecular weight is 958.22 g/mol. The structural formula is:
Everolimus Tablets are available for oral administration containing 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg of everolimus, USP. Each tablet contains the following inactive ingredients: anhydrous lactose, butylated hydroxytoluene, crospovidone, hypromellose and magnesium stearate.
How it works: Everolimus inhibits antigenic and interleukin (IL-2 and IL-15) stimulated activation and proliferation of T and B lymphocytes. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cf2dd54b-7a1d-4401-9a01-75e68235e433. Read the full official label on DailyMed.